Modular Medical stock rises after securing PBM contract

Modular Medical Inc (MODD) shares rose 2.3% after securing a contract with a national U.S. pharmacy benefit manager, making its Pivot insulin delivery system available through the PBM. The company aims to broaden patient access to its Pivot tubeless patch pump, a wearable insulin delivery platform for diabetes management.

Original reporting
Published Sep 4, 2026, 2:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 3:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$MODD
Bullish
high confidence
Mentioned
$MODD
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MODDBullishHigh
01

Why it matters

The PBM agreement represents a commercialization milestone that could accelerate revenue and market penetration for the Pivot patch pump.

02

Market read

The news is likely to lift MODD's stock and may positively influence other diabetes‑device firms.

03

What to watch

Potential regulatory hurdles for the Pivot system and competition from established insulin pump manufacturers may temper growth.

Relevance 7/10Novelty 8/10Timing: same-day announcement

Background

Modular Medical (NASDAQ:MODD) is a commercial‑stage medical‑device company focused on insulin delivery technologies.

Company-level read

Ticker impact

$MODDBullishHigh confidence
Context

Modular Medical announced a contract with a national U.S. pharmacy benefit manager to commercialize its Pivot insulin delivery system.

Expected impact

Potential short‑term upside of 3‑5% as investors price in the new revenue opportunity.

Evidence & confidence

A national PBM partnership is a material commercial milestone for a micro‑cap medical‑device firm, and the stock already rose 2.3% on the news.

Market effects

May boost sentiment for the broader diabetes‑device sector as a major PBM partnership signals payer acceptance.

Positive for U.S. healthcare and medical‑device stocks, especially those targeting insulin delivery.

Limited to U.S. market but could attract international investors seeking exposure to innovative diabetes technologies.

Counterpoint

The contract size is undisclosed; without clear revenue visibility, the price rally could be premature.

Key entities

  • Modular Medical Inc

    Developer of the Pivot insulin delivery system.

  • National U.S. Pharmacy Benefit Manager

    Large PBM that will make the Pivot system available to its network.

Related articles

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

Samsung Stocks Rise 2.31% in Seoul as Nvidia Beat Lifts Korean Chipmakers

Samsung Electronics (SSNLF) rose 2.31% in Seoul trading after Nvidia's strong earnings boosted Korean chipmakers. Nvidia's increased spending on memory and foundry capacity, areas where Samsung operates, contributed to the gain. Samsung Electro-Mechanics, an affiliate, saw a 7.43% increase after being named in a new supply deal with Nvidia. GuruFocus rates Samsung as fairly valued, with a GF Score of 95/100.

$BBWMed

Why Build-A-Bear Workshop Rallied on Wednesday

Build-A-Bear Workshop (BBW) shares rose 5.6% after appointing Holly Tybor as SVP and chief product and innovation officer. Tybor has 20+ years of retail experience and previously worked at Knitwell Group and Victoria's Secret. The company aims to leverage her expertise to drive product innovation and brand growth amid economic challenges.